1 Study Matches
Site for Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
This is a study of the drug DFMO (difluoromethylornithine) for medulloblastoma that has returned or not responded to treatment. DFMO is an oral drug that inhibits a certain enzyme (protein) in blood which is associated with a bad outcome in neuroblastoma cases. Cancer cells have pathways that drive the cancer to grow and DFMO targets the specific pathway of this enzyme to turn these cells off.
Suzanne Treadway - at firstname.lastname@example.org or 717-531-3097
Inclusion Criteria:You have had medulloblastoma that was either high risk or had relapsed or had not responded to therapy
You are 21 years old or younger
You must have no evidence of disease at this time
Exclusion Criteria:You are currently taking another study drug or an anticancer drug